Why it matters: Banksel told the FT that the drug maker would not seek emergency authorization for Food and Drug Administration approval for its vaccines for use in frontline medical personnel and at-risk individuals until November 25 at the earliest.
- He said the company would not seek FDA approval for use in the general population until the end of January.
- If the vaccine proves to be safe and effective, approval is unlikely to come until late April or early April.
What they are saying “I think it’s late [first quarter], soon [second quarter] According to the FT, Bansell said, “Approval is a reasonable timeline based on what we find from our vaccines.”
big picture: Modern’s vaccine is one of four currently in late stage trials in people in the US
- The Trump administration announced in August that it had purchased $ 1.5 billion or $ 15 per dose of 100 million doses of Modern’s experimental coronavirus vaccine.
- The president has repeatedly claimed that a vaccine will be available for wider distribution before the end of the year, although CDC Director Robert Redfield testified to Congress that it is more likely that a vaccine will be available by the second or third quarter of next 2021 Will not done.